NCT00665665View on ClinicalTrials.gov

Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers

PHASE1TerminatedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Metabolism and Nutrition DisorderObesity
Interventions
DRUG

NNC 0070-0002-0182

4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial

DRUG

placebo

Placebo for s.c. injection

DRUG

NNC 0070-0002-0182

12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial

DRUG

NNC 0070-0002-0182

32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial

DRUG

NNC 0070-0002-0182

60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial

Trial Locations (2)

47710

Novo Nordisk Investigational Site, Evansville

53704

Novo Nordisk Investigational Site, Madison

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00665665 - Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers | Biotech Hunter | Biotech Hunter